MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)*
Organization & Developments: Marinus
Parents
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)*
Children
*Drugs to treat serious central nervous system disorders.
*Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders
*Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders.
2016: Marinus Pharma's lead product candidate flunks late-stage study; shares crater 59% premarket - Marinus Pharmaceuticals (NASDAQ:MRNS)
2017: Marinus Pharmaceuticals: A Discarded CNS Gem Ready To Shine In 2017 - Marinus Pharmaceuticals (NASDAQ:MRNS)
2017: Marinus Pharmaceuticals: The Next Big Thing In CNS_seekingalpha
2018: Marinus Has A Long And Difficult Road Ahead In Postpartum Depression_seekingalpha.com
2018: Marinus Is Aiming For The Gold Standard In PPD - Marinus Pharmaceuticals (NASDAQ:MRNS)
2018: Marinus Pharmaceuticals - Be Greedy When Others Are Fearful - Marinus Pharmaceuticals (NASDAQ:MRNS)
2018: Marinus_Why This Hot Stock Could Spike 100% On Major Catalyst
2019: Marinus: Ganaxolone, Again, Proves No Better Than Placebo_seekingalpha.com
2019: What The Sage-217 Results In PPD Mean For Marinus - Marinus Pharmaceuticals (NASDAQ:MRNS)
2021: Mulling Over Marinus Pharmaceuticals
2022 Marinus Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_seekingalpha.com
2022: Marinus Pharmaceuticals: Positive News Flow Of Note_seekingalpha.com
2023: Marinus Pharmaceuticals: A Capital Raise Is On The Horizon_ seekingalpha.com
2024: Marinus lays off 20% of staff to steady ship after IV seizure med's phase 3 struggles_ fiercebiotech
Jumps
*Key People: Marinus
Finance & Acquisitions: Marinus